Helus Pharma Shares Plunge 33% Despite 10.4-Point Anxiety Improvement in Phase 2 Trial
Helus Pharma’s Phase 2 signal detection study in 36 generalized anxiety disorder patients showed a 10.4-point improvement over placebo with no serious adverse events. Shares plunged 33% to $6.41, trading over 10% below its 20-day SMA and near 52-week lows amid mixed technical indicators.
1. Phase 2 Signal Detection Study
Helus Pharma conducted a Phase 2 signal detection trial in 36 generalized anxiety disorder patients, randomizing them to HLP004 or placebo alongside standard care. The study recorded a 10.4-point mean improvement in anxiety symptoms beyond standard treatment and reported no drug-related serious adverse events or suicidality signals.
2. Six-Month Response and Remission Rates
At six months, the pooled population achieved a 67% response rate and 39% remission. The 20 mg dosing arm saw 59% responders and 32% remitters at week six, while the 2 mg arm delivered 30% response and remission rates in the same period.
3. Stock Reaction and Technical Indicators
Helus Pharma shares fell 33% to $6.41, trading 10.4% below their 20-day simple moving average and 12.5% below the 100-day SMA. The RSI stands at 50.00 with MACD at 0.10 below its 0.15 signal line, indicating mixed momentum as the stock nears 52-week lows, with key support at $7.50 and resistance at $8.00.